New LinkedIn group of the WG on Myocardial Function!
Wolfgang Linke, WG Chair
Hello, members and friends of the ESC Working Group on Myocardial Function,
We’re thrilled to officially join the LinkedIn community! As WG MF, we explore, share, and collaborate on all aspects of science and translational medicine related to the cardiovascular system within the frames of the ESC.
We are a passionate team of health professionals, researchers, and enthusiasts dedicated to advancing basic, bench-to-bedside, and clinical knowledge.
What to expect:
- Updates on our latest projects, publications, conferences, and interesting cardiovascular science.
- Insights into scientific breakthroughs and industry trends.
- Opportunities for collaboration and engagement.
We believe in the power of shared knowledge and meaningful conversations. Let’s connect, inspire, and grow together. Stay tuned for exciting content, and don’t hesitate to say hello or share your thoughts — we’d love to hear from you! In our working group you can become part of an engaging community driving cardiovascular science and medicine. Let's exchange, collaborate, and make a difference together!
Please apply to join the group through this link: https://lnkd.in/d4DNc2vG
BJP Themed Issue “Noncoding RNA therapeutics”
Yvan Devaux & Serena Zacchigna
European Society of Cardiology Working Group on Myocardial Function members Yvan Devaux and Serena Zacchigna have coordinated and guest-edited a Themed Issue “Noncoding RNA therapeutics” in the British Journal of Pharmacology. This Themed Issue gathers seven commissioned review articles and five original research articles focused on the potential of noncoding RNA molecules as novel therapeutic targets. Contributing authors are mostly from three COST (Cooperation in Science and Technology) Actions, which are multidisciplinary networks funded by the European Commission: the Cardioprotection COST Action focusing on novel cardioprotective therapies (www.cardioprotection.eu)1, the CardioRNA COST Action catalyzing collaborative research in the cardiovascular RNA field (www.cardiorna.eu)2, and the AtheroNET COST Action on multiomics and AI in atherosclerotic cardiovascular disease (www.atheronet.eu)3.
Several RNA-based strategies are now approved for clinical use, e.g., the siRNA Inclisiran-Leqvio® which targets PCSK9 and is used to lower cholesterol levels in blood. However, the therapeutic and biomarker values of noncoding RNAs remain underexplored 4. More funding and research are needed to fully realize the potential of noncoding RNAs to aid in disease prevention and management 5. Noncoding RNAs hold the potential to be used as Theranostics, as they could identify patients who would also benefit from a RNA-directed therapy 6, 7.
Over the past three decades, the field of noncoding RNAs has seen a tremendous development, as attested by three Nobel Prizes related to RNAs in the past five years. In 2020, the Royal Swedish Academy of Sciences attributed the Nobel Prize in Chemistry to Professors Doudna and Charpentier for their research on gene editing. Three years later, in 2023, the Nobel Prize in Physiology or Medicine was awarded to Professors Karikó and Weissman for their work on mRNA modification. And, on 7 October this year, Professors Ambros and Ruvkun received the Nobel Prize in Physiology or Medicine for their discovery and characterization of microRNAs.
We strongly believe that RNA therapeutics holds capacity to aid in improving personalized healthcare and clinical outcomes of patients, not only in the cardiovascular field. This Themed Issue “Noncoding RNA therapeutics” in the British Journal of Pharmacology is a forum to learn about RNA therapeutics and help defining future research directions.
HFA Winter Research Meeting on Translational Heart Failure Research
Arantxa González, WG Communication Coordinator
This past January, we had the pleasure of attending the HFA Winter Research Meeting on Translational Heart Failure Research held in Vienna, organized by the Heart Failure Association in collaboration with the ESC Working Group on Myocardial Function.
The meeting showcased exceptional basic and translational research, featuring outstanding speakers and remarkable contributions from early-stage researchers.
We thoroughly enjoyed connecting with members of the Working Group and fellow colleagues committed to advancing translational heart failure research. The event provided ample opportunities for discussion and lively interaction, leaving us all inspired with innovative ideas for our projects.
Our Working Group played an active role in organizing the event. In addition, lectures were delivered by our Chair Wolfgang Linke, Past Chair Dana Dawson, Chair-elect Luc Bertrand, and Nucleus members Jolanda van der Welden and Frank Lezoualc'h.
Congratulations to the Awardees!
- The Brutsaert Lecture: Prof. Gianluigi Condorelli (Humanitas Research Hospital, Milan, Italy).
- The Guido Tarone Award: Dr. Andrea Ruiz Velasco Hernández (Paris Cardiovascular Research Center (PARCC), Paris, France).
Young Investigator Competition
We extend our heartfelt congratulations to all early-stage researchers for their excellent presentations. Special recognition goes to the awardees of the Young Investigator competition:
- Winner: Dr. Roman Vuerich (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy)
- Runners-up:
- Dr. Era Gorica (Center for Translational and Experimental Cardiology, Zurich, Switzerland)
- Paulina Hartmann (University Hospital Münster, Germany)
Once again, congratulations to all participants for their inspiring work!
Our mission: To reduce the burden of cardiovascular disease.